Rocketing to a price of $38.32 during today's morning trading session, shares of Halozyme Therapeutics are still -26.02% below their average target price of $51.8. Could there be more upside potential for the stock? Analysts are giving HALO an average rating of buy and target prices ranging from $28.0 to $72.0 dollars per share.
For the greater market's outlook on the stock, we can use Halozyme Therapeutics's short interest as a proxy. The short interest represents the proportion of the float's shares that are tied to short positions, meaning that the investor believes the stock will decline in the future. Here, the stock's short interest is 6.6% which means the outlook is split.
Short selling involves borrowing shares and then selling them at current market prices. In the successful version of the strategy, the shares are purchased at a lower price at some time in the future. The investor then returns the shares to the lender, and keeps the profit made on the sell/buy transaction.
Another way to gauge the sentiment on Halozyme Therapeutics is to look at the percentage of institutions that are invested in the stock. In this case, 96.6% of the shares are held by pension, mutual, and hedge funds, which shows that these institutions probably have strong confidence in the stock.
If institutions are invested in a particular stock, it shows in most cases that they have performed quality research and concluded that it is a good investment. In some cases, however, increases in institutional ownership could be a sign of a takeover attempt or proxy fight, which can actually injure share prices. Also, institutions are not infallible, and can certainly make miscalculations -- often with spectacular results.
Overall, there is mixed market sentiment on Halozyme Therapeutics because its an analyst consensus of strong upside potential, a buy rating, an average amount of shares sold short, and a significant number of institutional investors. Warren Buffett famously said that in the short term, markets are voting mechanisms, but in the long term, they are weighing mechanisms. This means that long term investors should be aware of a stock's fundamentals before committing.
Buffett was one of the fist investors to focus on free cash flow as a yardstick for a company's health. Here are HALO's recent cash flows:
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-21 | 240,110 | 21,196 | 218,914 | -27.25 |
| 2022-02-22 | 299,440 | -1,457 | 300,897 | 428.98 |
| 2021-02-23 | 55,454 | -1,428 | 56,882 | 169.89 |
| 2020-02-24 | -85,423 | -4,040 | -81,383 | -81.51 |
| 2019-02-21 | -49,500 | -4,663 | -44,837 | -133.11 |
| 2018-02-20 | 134,053 | -1,350 | 135,403 |
